GlaxoSmithKline faces more Avandia fallout
Matthew Arnold,Marc Iskowitz
June 05 2007
GlaxoSmithKline is in Congressional crosshairs over its marketing of Avandia, and investors arent happy either.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.